bioRxivNeurosciencePreprint
Neighbouring modifications interfere with the detection of phosphorylated alpha-synuclein at Serine 129: Revisiting the specificity of pS129 antibodies
Hilal Ahmed LashueliD, Anne‐Laure Mahul‐MellieriD, Salvatore NovelloiD, Ramanath Narayana HegdeiD, Yllza JasiqiiD, Melek Firat AltayiD, Sonia Donzelli, Sean M. DeGuire, Ritwik Burai, Pedro MagalhãesiD, Anass ChikiiD, Jonathan RicciiD, Manel L. N. BoussoufiD, Ahmed SadekiD, Erik StoopsiD, Christian IseliiD, Nicolas GuexiD
Abstract
Alpha-synuclein (aSyn) within Lewy bodies, Lewy neurites, and other pathological hallmarks of Parkinsons disease and synucleinopathies have consistently been shown to accumulate in aggregated and phosphorylated forms of the protein, predominantly at Serine 129 (S129). Antibodies against phosphorylated S129 (pS129) have emerged as the primary tools to investigate, monitor, and quantify aSyn pathology in the brain and peripheral tissues. However, most of the antibodies and immunoassays aimed at detecting pS129-aSyn were developed based on the assumption that neighbouring post-translational modifications (PTMs) either do not co-occur with pS129 or do not influence its detection. Herein, we demonstrate that the co-occurrence of multiple pathology-associated C-terminal PTMs (e.g., phosphorylation at Tyrosine 125 or truncation at residue 133 or 135) differentially influences the detection of pS129-aSyn species by pS129-aSyn antibodies. These observations prompted us to systematically reassess the specificity of the most commonly used pS129 antibodies against monomeric and aggregated forms of pS129-aSyn in mouse brain slices, primary neurons, mammalian cells and seeding models of aSyn pathology formation. We identified two antibodies that are insensitive to pS129 neighbouring PTMs. However, consistent with previous reports, most pS129 antibodies showed cross-reactivity towards other proteins and often detected low and high molecular weight bands in aSyn knock-out samples that could be easily mistaken for monomeric or High Molecular Weight aggregates of aSyn. Our observations suggest that the pS129 antibodies do not capture the biochemical and morphological diversity of aSyn pathology. They also underscore the need for more specific pS129 antibodies, more thorough characterization and validation of existing antibodies, and the use of the appropriate protein standards and controls in future studies.
- Citations
- 2
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Specific Detection of Endogenous S129 Phosphorylated α-Synuclein in Tissue Using Proximity Ligation Assay
Ryan Arlinghaus, Michiyo Iba, … Natalie Landeck·bioRxiv·Sep 28, 2021
- Development and validation of an expanded antibody toolset that captures alpha-synuclein pathological diversity in Lewy body diseases
Melek Firat Altay, Senthil T. Kumar, … Hilal Ahmed Lashuel·npj Parkinson s DiseasePeer-reviewed·Dec 7, 2023
- Subcellular orchestration of alpha-synuclein variants in Parkinson’s disease brains revealed by 3D multicolor STED microscopy
Tim E. Moors, Christina A. Maat, … Wilma D. J. van de Berg·bioRxiv·Sep 17, 2019
- Prominent astrocytic alpha-synuclein pathology with unique post-translational modification signatures unveiled across Lewy body disorders
Melek Firat Altay, Alan King Lun Liu, … Hilal Ahmed Lashuel·Acta Neuropathologica CommunicationsPeer-reviewed·Nov 12, 2022
- Pathological relevance of post-translationally modified alpha-synuclein (pSer87, pSer129, nTyr39) in idiopathic Parkinson's disease and Multiple System Atrophy.
Berkiye Sonustun, Melek Firat Altay, … Rina Bandopadhyay·CellsPeer-reviewed·Mar 6, 2022
- Characterization of pathology-inducing α-synuclein species from human diseased brain tissue
John D. Graef, Nina Hoque, … Jere E. Meredith·bioRxiv·Mar 25, 2019